Authors of a recent editorial appearing in the Journal of the National Cancer Institute say opening clinical trials in ...

Acalabrutinib combined with lenalidomide and rituximab shows promising results as a frontline treatment for follicular lymphoma, achieving high response rates.

Monjuvi, combined with Rituxan and Revlimid, extends progression-free survival to 22 months, reducing disease progression risk by over 50%. The inMIND trial's design and diverse patient population ...

Findings from an FDA general site inspection were enough to delay the approval of odronextamab, as well as other pending applications. The Food and Drug Administration (FDA) has issued another ...

Early rituximab monotherapy led to a substantial delay in the need for new treatment in patients with advanced stage, asymptomatic, low tumour burden follicular lymphoma. After a median follow-up ...

The global thyroid cancer diagnostics market size is calculated at USD 3.27 billion in 2025 and is expected to reach around ...

Association between progression-free survival and overall survival in relapsed/refractory diffuse large B-cell lymphoma in the CAR T-cell era: A surrogate endpoint analysis. This is an ASCO Meeting ...

(a) The smear is composed of blood only (smear, Diff-Quik stain). (b) The smear shows foamy macrophages and degenerated cyst fluid, with no follicular cells (smear, Diff-Quik stain). (c) Scant ...